Portal de Periódicos da CAPES

Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4

2019; Multidisciplinary Digital Publishing Institute; Volume: 8; Issue: 5 Linguagem: Inglês

10.3390/cells8050416

2073-4409

Nadia Marascio, Maria Mazzitelli, Grazia Pavia, Aldo Giancotti, Giorgio Settimo Barreca, Chiara Costa, Vincenzo Pisani, Giuseppe Greco, Francesca Serapide, Enrico Maria Trecarichi, Francesco Casalinuovo, Maria Carla Liberto, Giovanni Matera, Carlo Torti,

Liver Disease Diagnosis and Treatment

Direct-acting antiviral drugs to cure infections with Hepatitis C virus (HCV) achieve a sustained virological response (SVR) in more than 90% of adult patients. At present, clinical trials are ongoing and real-life data are still limited in children. Herein, we report two cases of pediatric patients treated with fixed-dose combination of sofosbuvir/ledipasvir, already approved to treat HCV4 genotype. Both young girls achieved SVR even though HCV4 isolates carried L28M and M31L NS5A resistance-associated substitutions (RASs). Therefore, possible effects of these RASs merit further study, especially in children.